GTx, Inc. (NASDAQ:GTXI) has earned a consensus broker rating score of 3.00 (Hold) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a hold recommendation.

Brokers have set a 12 month consensus target price of $1.75 for the company and are expecting that the company will post ($0.22) EPS for the current quarter, according to Zacks. Zacks has also assigned GTX an industry rank of 51 out of 256 based on the ratings given to related companies.

A number of research firms recently commented on GTXI. ValuEngine raised GTX from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research lowered GTX from a “buy” rating to a “hold” rating in a research report on Wednesday, November 21st. Stifel Nicolaus lowered GTX from a “buy” rating to a “hold” rating in a research report on Friday, September 21st. Robert W. Baird lowered GTX from an “outperform” rating to a “neutral” rating and set a $17.00 price target for the company. in a research report on Friday, September 21st. Finally, BidaskClub lowered GTX from a “buy” rating to a “hold” rating in a research report on Thursday, September 20th.

Shares of NASDAQ:GTXI traded up $0.06 during trading on Friday, reaching $1.02. 316,647 shares of the stock were exchanged, compared to its average volume of 407,902. GTX has a 1-year low of $0.74 and a 1-year high of $25.60. The firm has a market capitalization of $23.73 million, a price-to-earnings ratio of -0.58 and a beta of 2.14.

GTX (NASDAQ:GTXI) last issued its earnings results on Thursday, November 15th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.09). As a group, research analysts anticipate that GTX will post -1.65 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc grew its holdings in GTX by 19.3% during the third quarter. Vanguard Group Inc now owns 467,463 shares of the biopharmaceutical company’s stock valued at $734,000 after purchasing an additional 75,539 shares during the period. Vanguard Group Inc. boosted its stake in shares of GTX by 19.3% in the third quarter. Vanguard Group Inc. now owns 467,463 shares of the biopharmaceutical company’s stock worth $734,000 after acquiring an additional 75,539 shares during the period. Vivo Capital LLC bought a new position in shares of GTX in the third quarter worth about $165,000. Bridgeway Capital Management Inc. bought a new position in shares of GTX in the third quarter worth about $431,000. Finally, BlackRock Inc. boosted its stake in shares of GTX by 23.2% in the third quarter. BlackRock Inc. now owns 480,618 shares of the biopharmaceutical company’s stock worth $755,000 after acquiring an additional 90,468 shares during the period. 12.34% of the stock is owned by institutional investors and hedge funds.

GTX Company Profile

GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.

Featured Story: Trading Strategy Methods and Types

Get a free copy of the Zacks research report on GTX (GTXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.